Current Clinical Management and Challenges in Lysosomal Disorders

Lysosomal & Rare Disorders Research & Treatment Center

GRIDS-2022

Current Clinical Management and Challenges in Lysosomal Disorders

January 23, 2023 – January 23, 2024

Estimated time to complete: 2.0 hours

NO LONGER AVAILABLE FOR CREDIT

Continuing Education Information

This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.

Speakers

Orna Staretz, MD, Ben Gurion University of the Negev, Israel
Sonata Jodele, MD, Cincinnati Children’s Hospital, Blood, and Bone Marrow Transplantation Program
Debra S. Regier, MD, PhD, Children’s National Medical Center
Walla Al-Hertani, MD, Boston’s Children’s Hospital

Disclosures

AffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and will be stated prior to the start of each session.

Faculty disclosures

Orna Staretz, MD, Ben Gurion University of the Negev, Israel
No relevant financial arrangements with ineligible companies to disclose.
No discussion of unapproved drug or product uses.

Sonata Jodele, MD, Cincinnati Children’s Hospital, Blood, and Bone Marrow Transplantation Program
Advisory Board: Sobi
Lecture Honorarium: Omeros, Alexion, Medscape
Will discuss non-FDA uses of drug products and/or devices and their unlabeled indications and will disclose to the audience when this discussion takes place.

Debra S. Regier, MD, PhD, Children’s National Medical Center
No relevant financial arrangements with ineligible companies to disclose.
Will discuss non-FDA uses of drug products and/or devices and their unlabeled indications and will disclose to the audience when this discussion takes place.

Walla Al-Hertani, MD, Boston’s Children’s Hospital
No relevant financial arrangements with ineligible companies to disclose.
No discussion of unapproved drug or product uses.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.

Learning Objectives

At the end of this activity, participants should be able to address one or more of the following:

• Review the importance of early use of ERT
• Review safety concerns that may occur following gene therapy
• Review the pros and cons of neonatal screening for LSDs.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 2.0 hours of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors
Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational grant support for GRIDS 2022 provided by Sanofi Genzyme, Takeda Pharmaceutical Company, Chiesi USA, Amicus Therapeutics, and BioMarin.

Participation Costs

There is no cost to participate in this activity.

CME Inquiries

For all CME policy-related inquiries, please contact us at [email protected].
Send customer support requests to [email protected].